 Daniel Bowles
Concepts (345)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 30 | 2024 | 2162 | 3.340 |
Why?
| | Head and Neck Neoplasms | 16 | 2023 | 557 | 2.910 |
Why?
| | Salivary Gland Neoplasms | 8 | 2023 | 38 | 2.880 |
Why?
| | Carcinoma, Squamous Cell | 14 | 2019 | 641 | 2.250 |
Why?
| | Protein Kinase Inhibitors | 14 | 2024 | 918 | 2.180 |
Why?
| | Pyridines | 13 | 2024 | 560 | 2.040 |
Why?
| | Thyroid Neoplasms | 9 | 2024 | 320 | 1.900 |
Why?
| | Molecular Targeted Therapy | 7 | 2021 | 420 | 1.670 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 8 | 2023 | 1125 | 1.630 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2023 | 1075 | 1.620 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 1791 | 1.500 |
Why?
| | Neoplasms | 20 | 2024 | 2731 | 1.460 |
Why?
| | Protein-Tyrosine Kinases | 4 | 2021 | 428 | 1.450 |
Why?
| | Anilides | 6 | 2024 | 80 | 1.360 |
Why?
| | Gonanes | 7 | 2016 | 27 | 1.350 |
Why?
| | Lung Neoplasms | 10 | 2023 | 2554 | 1.330 |
Why?
| | Proto-Oncogene Proteins | 6 | 2021 | 621 | 1.330 |
Why?
| | Thyroid Carcinoma, Anaplastic | 3 | 2020 | 33 | 1.270 |
Why?
| | Cetuximab | 7 | 2018 | 106 | 1.260 |
Why?
| | Biomarkers, Tumor | 8 | 2020 | 1250 | 1.250 |
Why?
| | Adenocarcinoma | 7 | 2024 | 897 | 1.230 |
Why?
| | Phosphatidylinositol 3-Kinases | 8 | 2017 | 364 | 0.830 |
Why?
| | Mutation | 13 | 2024 | 4006 | 0.760 |
Why?
| | Carcinoma | 3 | 2019 | 230 | 0.720 |
Why?
| | Drugs, Investigational | 2 | 2011 | 31 | 0.690 |
Why?
| | Phytotherapy | 2 | 2012 | 82 | 0.690 |
Why?
| | Neoplasm Staging | 15 | 2019 | 1397 | 0.690 |
Why?
| | Cisplatin | 6 | 2024 | 328 | 0.680 |
Why?
| | Pyrazoles | 5 | 2023 | 482 | 0.630 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 98 | 0.630 |
Why?
| | Disease-Free Survival | 10 | 2017 | 713 | 0.620 |
Why?
| | Papillomaviridae | 4 | 2019 | 121 | 0.620 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 191 | 0.610 |
Why?
| | Taxoids | 3 | 2015 | 105 | 0.610 |
Why?
| | Quinolines | 5 | 2024 | 169 | 0.610 |
Why?
| | Hedgehog Proteins | 3 | 2015 | 200 | 0.600 |
Why?
| | Carcinoma, Renal Cell | 3 | 2017 | 221 | 0.600 |
Why?
| | Humans | 89 | 2024 | 141284 | 0.590 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2024 | 840 | 0.560 |
Why?
| | Tumor Suppressor Proteins | 2 | 2018 | 325 | 0.560 |
Why?
| | Marijuana Smoking | 2 | 2012 | 262 | 0.550 |
Why?
| | Pyrimidines | 5 | 2023 | 510 | 0.550 |
Why?
| | Middle Aged | 43 | 2024 | 34658 | 0.520 |
Why?
| | Kidney Neoplasms | 3 | 2017 | 400 | 0.520 |
Why?
| | Colorectal Neoplasms | 2 | 2016 | 811 | 0.520 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 17 | 0.520 |
Why?
| | Aged | 39 | 2024 | 24836 | 0.510 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2017 | 60 | 0.510 |
Why?
| | Carcinoma, Transitional Cell | 4 | 2017 | 70 | 0.500 |
Why?
| | Carcinoma, Ductal | 1 | 2016 | 10 | 0.500 |
Why?
| | Adenoma, Pleomorphic | 1 | 2016 | 10 | 0.500 |
Why?
| | Gene Rearrangement | 2 | 2018 | 148 | 0.490 |
Why?
| | Sulfones | 2 | 2014 | 127 | 0.490 |
Why?
| | Cannabinoids | 2 | 2024 | 178 | 0.480 |
Why?
| | Glycine | 2 | 2014 | 187 | 0.480 |
Why?
| | Maximum Tolerated Dose | 5 | 2017 | 204 | 0.450 |
Why?
| | Drug Interactions | 6 | 2017 | 404 | 0.420 |
Why?
| | Enzyme Inhibitors | 3 | 2014 | 835 | 0.420 |
Why?
| | Melanoma | 1 | 2021 | 786 | 0.420 |
Why?
| | Pyrroles | 1 | 2014 | 207 | 0.410 |
Why?
| | Gene Fusion | 3 | 2023 | 22 | 0.400 |
Why?
| | Iodine Radioisotopes | 5 | 2024 | 138 | 0.400 |
Why?
| | Signal Transduction | 8 | 2018 | 5116 | 0.400 |
Why?
| | Phenylurea Compounds | 4 | 2024 | 100 | 0.400 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2012 | 226 | 0.390 |
Why?
| | Genetic Variation | 1 | 2018 | 993 | 0.390 |
Why?
| | Male | 44 | 2024 | 70140 | 0.390 |
Why?
| | Lymph Nodes | 4 | 2017 | 494 | 0.380 |
Why?
| | Indazoles | 3 | 2019 | 77 | 0.370 |
Why?
| | Female | 45 | 2024 | 75814 | 0.370 |
Why?
| | Quinazolines | 1 | 2013 | 260 | 0.360 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 4 | 2017 | 100 | 0.360 |
Why?
| | Aged, 80 and over | 15 | 2024 | 7948 | 0.350 |
Why?
| | Treatment Outcome | 15 | 2024 | 11216 | 0.350 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 125 | 0.350 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2024 | 908 | 0.340 |
Why?
| | Neoplasm Metastasis | 6 | 2021 | 674 | 0.330 |
Why?
| | Proto-Oncogene Proteins c-ret | 4 | 2023 | 35 | 0.320 |
Why?
| | Adult | 26 | 2024 | 39319 | 0.300 |
Why?
| | Prognosis | 9 | 2021 | 4080 | 0.290 |
Why?
| | ErbB Receptors | 4 | 2017 | 612 | 0.280 |
Why?
| | Benzamides | 3 | 2022 | 218 | 0.280 |
Why?
| | Pharmacogenomic Variants | 2 | 2018 | 32 | 0.270 |
Why?
| | Papillomavirus Infections | 3 | 2022 | 364 | 0.260 |
Why?
| | Nitriles | 2 | 2022 | 189 | 0.260 |
Why?
| | Urologic Neoplasms | 2 | 2017 | 30 | 0.260 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2007 | 81 | 0.260 |
Why?
| | Mitoxantrone | 1 | 2006 | 14 | 0.250 |
Why?
| | Platinum | 2 | 2024 | 51 | 0.250 |
Why?
| | Xenograft Model Antitumor Assays | 7 | 2024 | 917 | 0.250 |
Why?
| | Enterobacter | 1 | 2006 | 8 | 0.250 |
Why?
| | Tooth Diseases | 1 | 2006 | 13 | 0.250 |
Why?
| | Esophageal and Gastric Varices | 1 | 2006 | 35 | 0.240 |
Why?
| | Enterobacteriaceae Infections | 1 | 2006 | 42 | 0.240 |
Why?
| | Gene Expression Profiling | 5 | 2018 | 1761 | 0.240 |
Why?
| | Salivary Glands | 2 | 2023 | 36 | 0.230 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2016 | 54 | 0.230 |
Why?
| | Acute Kidney Injury | 3 | 2018 | 822 | 0.230 |
Why?
| | Animals | 16 | 2024 | 37328 | 0.230 |
Why?
| | Serotonin 5-HT3 Receptor Antagonists | 1 | 2024 | 5 | 0.230 |
Why?
| | Chemoradiotherapy | 4 | 2020 | 232 | 0.230 |
Why?
| | Clinical Trials as Topic | 3 | 2018 | 1035 | 0.220 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2024 | 225 | 0.220 |
Why?
| | Receptors, Estrogen | 1 | 2007 | 412 | 0.220 |
Why?
| | Antiemetics | 1 | 2024 | 48 | 0.220 |
Why?
| | Immunotherapy | 2 | 2023 | 641 | 0.220 |
Why?
| | Cannabis | 1 | 2011 | 510 | 0.210 |
Why?
| | Registries | 2 | 2016 | 2205 | 0.210 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2017 | 255 | 0.210 |
Why?
| | Liver Cirrhosis | 1 | 2006 | 283 | 0.210 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2023 | 18 | 0.210 |
Why?
| | Combined Modality Therapy | 4 | 2018 | 1243 | 0.210 |
Why?
| | Models, Biological | 3 | 2024 | 1810 | 0.200 |
Why?
| | Bacteremia | 1 | 2006 | 218 | 0.200 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2019 | 1439 | 0.200 |
Why?
| | Administration, Oral | 3 | 2014 | 825 | 0.200 |
Why?
| | Phenylthiohydantoin | 1 | 2022 | 44 | 0.190 |
Why?
| | Medical Marijuana | 1 | 2024 | 124 | 0.180 |
Why?
| | Survival Rate | 5 | 2021 | 1979 | 0.180 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2017 | 383 | 0.180 |
Why?
| | Radiation Pneumonitis | 1 | 2021 | 31 | 0.180 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2013 | 191 | 0.180 |
Why?
| | Survival Analysis | 4 | 2020 | 1322 | 0.180 |
Why?
| | Referral and Consultation | 1 | 2007 | 802 | 0.180 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2021 | 34 | 0.170 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 428 | 0.170 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2021 | 63 | 0.170 |
Why?
| | Disease Susceptibility | 2 | 2020 | 351 | 0.160 |
Why?
| | Adrenocortical Carcinoma | 1 | 2021 | 66 | 0.160 |
Why?
| | Gene Expression | 2 | 2015 | 1490 | 0.160 |
Why?
| | Cystectomy | 2 | 2017 | 42 | 0.160 |
Why?
| | SEER Program | 1 | 2021 | 219 | 0.160 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 18 | 0.160 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 910 | 0.160 |
Why?
| | DNA Mutational Analysis | 2 | 2018 | 396 | 0.150 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2006 | 653 | 0.150 |
Why?
| | Lymph Node Excision | 2 | 2017 | 169 | 0.150 |
Why?
| | Tracheal Neoplasms | 1 | 2019 | 12 | 0.150 |
Why?
| | United States | 8 | 2021 | 15298 | 0.150 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2020 | 112 | 0.150 |
Why?
| | Smad4 Protein | 1 | 2019 | 35 | 0.150 |
Why?
| | Radiosurgery | 1 | 2022 | 389 | 0.150 |
Why?
| | Alphapapillomavirus | 2 | 2016 | 38 | 0.140 |
Why?
| | Benzazepines | 1 | 2018 | 35 | 0.140 |
Why?
| | Prostatic Neoplasms | 1 | 2006 | 1050 | 0.140 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 62 | 0.140 |
Why?
| | Genomics | 3 | 2021 | 811 | 0.140 |
Why?
| | Risk | 1 | 2021 | 903 | 0.140 |
Why?
| | Chromosome Aberrations | 1 | 2019 | 161 | 0.140 |
Why?
| | Disease Management | 2 | 2020 | 634 | 0.140 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 48 | 0.140 |
Why?
| | Tissue Fixation | 1 | 2017 | 36 | 0.140 |
Why?
| | Palliative Care | 2 | 2018 | 820 | 0.140 |
Why?
| | Paraffin Embedding | 1 | 2017 | 32 | 0.130 |
Why?
| | Oncogenes | 1 | 2018 | 119 | 0.130 |
Why?
| | Erlotinib Hydrochloride | 1 | 2017 | 69 | 0.130 |
Why?
| | Smokers | 1 | 2018 | 146 | 0.130 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2017 | 20 | 0.130 |
Why?
| | Formaldehyde | 1 | 2017 | 65 | 0.130 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 136 | 0.130 |
Why?
| | Gene Deletion | 1 | 2019 | 384 | 0.130 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 159 | 0.130 |
Why?
| | Neoplasm Grading | 1 | 2018 | 311 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 282 | 0.130 |
Why?
| | Gene Frequency | 1 | 2018 | 488 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 82 | 0.130 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 44 | 0.130 |
Why?
| | Salivary Ducts | 1 | 2016 | 2 | 0.130 |
Why?
| | Laryngeal Neoplasms | 1 | 2016 | 34 | 0.120 |
Why?
| | Hospice and Palliative Care Nursing | 1 | 2018 | 87 | 0.120 |
Why?
| | Carboplatin | 1 | 2016 | 145 | 0.120 |
Why?
| | Muscle, Smooth | 1 | 2017 | 150 | 0.120 |
Why?
| | Patient Navigation | 1 | 2018 | 98 | 0.120 |
Why?
| | Nomograms | 1 | 2016 | 58 | 0.120 |
Why?
| | Database Management Systems | 1 | 2016 | 51 | 0.120 |
Why?
| | Prospective Studies | 7 | 2024 | 7805 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2047 | 0.120 |
Why?
| | Disease Progression | 4 | 2018 | 2808 | 0.120 |
Why?
| | Young Adult | 5 | 2021 | 13727 | 0.120 |
Why?
| | Population Surveillance | 1 | 2019 | 481 | 0.120 |
Why?
| | Computational Biology | 2 | 2018 | 663 | 0.120 |
Why?
| | Angiopoietin-1 | 1 | 2015 | 11 | 0.120 |
Why?
| | Angiopoietin-2 | 1 | 2015 | 15 | 0.120 |
Why?
| | Incidence | 2 | 2019 | 2809 | 0.110 |
Why?
| | Radiotherapy | 1 | 2016 | 204 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2021 | 16447 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2017 | 249 | 0.110 |
Why?
| | Breast Neoplasms | 1 | 2007 | 2246 | 0.110 |
Why?
| | Genetic Testing | 1 | 2018 | 462 | 0.110 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 26 | 0.110 |
Why?
| | Retreatment | 1 | 2014 | 74 | 0.110 |
Why?
| | Hospice Care | 1 | 2018 | 204 | 0.110 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2014 | 19 | 0.110 |
Why?
| | Piperazines | 2 | 2018 | 375 | 0.110 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2014 | 19 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 438 | 0.100 |
Why?
| | Paclitaxel | 1 | 2015 | 236 | 0.100 |
Why?
| | Neoplastic Stem Cells | 1 | 2018 | 411 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2018 | 695 | 0.100 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 543 | 0.100 |
Why?
| | ras Proteins | 1 | 2014 | 145 | 0.100 |
Why?
| | Veratrum Alkaloids | 1 | 2013 | 20 | 0.100 |
Why?
| | Proportional Hazards Models | 4 | 2017 | 1268 | 0.100 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1244 | 0.100 |
Why?
| | Sulfonamides | 1 | 2017 | 576 | 0.100 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 249 | 0.100 |
Why?
| | PTEN Phosphohydrolase | 1 | 2014 | 162 | 0.100 |
Why?
| | Pilot Projects | 2 | 2015 | 1820 | 0.100 |
Why?
| | Cell Cycle Proteins | 2 | 2014 | 628 | 0.100 |
Why?
| | Imatinib Mesylate | 1 | 2012 | 80 | 0.090 |
Why?
| | Dasatinib | 1 | 2012 | 57 | 0.090 |
Why?
| | Risk Assessment | 2 | 2019 | 3522 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 672 | 0.090 |
Why?
| | Thiazoles | 1 | 2012 | 133 | 0.090 |
Why?
| | Hematopoietic Stem Cells | 1 | 2015 | 408 | 0.090 |
Why?
| | Biomarkers | 3 | 2018 | 4180 | 0.090 |
Why?
| | Aniline Compounds | 1 | 2012 | 120 | 0.090 |
Why?
| | Smoking | 1 | 2019 | 1576 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2012 | 71 | 0.090 |
Why?
| | Biological Availability | 1 | 2011 | 137 | 0.090 |
Why?
| | Mice | 7 | 2024 | 17969 | 0.090 |
Why?
| | Evidence-Based Medicine | 2 | 2012 | 717 | 0.090 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2011 | 26 | 0.090 |
Why?
| | Imidazoles | 1 | 2012 | 251 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2024 | 547 | 0.080 |
Why?
| | Propensity Score | 3 | 2017 | 337 | 0.080 |
Why?
| | Adolescent | 5 | 2022 | 22116 | 0.080 |
Why?
| | Tumor Microenvironment | 1 | 2015 | 711 | 0.080 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3502 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1764 | 0.080 |
Why?
| | Phenotype | 1 | 2018 | 3172 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2366 | 0.080 |
Why?
| | Kidney | 1 | 2017 | 1482 | 0.080 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2024 | 108 | 0.070 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1505 | 0.070 |
Why?
| | Adaptation, Psychological | 1 | 2014 | 680 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1282 | 0.070 |
Why?
| | Axilla | 1 | 2007 | 48 | 0.070 |
Why?
| | Cohort Studies | 4 | 2022 | 5809 | 0.070 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2019 | 51 | 0.070 |
Why?
| | Neoadjuvant Therapy | 2 | 2022 | 429 | 0.070 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2007 | 115 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2014 | 2815 | 0.060 |
Why?
| | Transcription Factors | 1 | 2014 | 1706 | 0.060 |
Why?
| | Mastectomy | 1 | 2007 | 152 | 0.060 |
Why?
| | Ligation | 1 | 2006 | 93 | 0.060 |
Why?
| | Caregivers | 1 | 2014 | 940 | 0.060 |
Why?
| | Pain | 1 | 2011 | 779 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2014 | 1124 | 0.060 |
Why?
| | Creatinine | 2 | 2018 | 491 | 0.060 |
Why?
| | Fatal Outcome | 1 | 2006 | 309 | 0.060 |
Why?
| | Receptors, Progesterone | 1 | 2007 | 337 | 0.060 |
Why?
| | Lymphatic Metastasis | 2 | 2017 | 327 | 0.060 |
Why?
| | Neoplasm Invasiveness | 2 | 2017 | 510 | 0.060 |
Why?
| | Granisetron | 1 | 2024 | 6 | 0.060 |
Why?
| | Quinuclidines | 1 | 2024 | 9 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2021 | 1992 | 0.060 |
Why?
| | Ondansetron | 1 | 2024 | 19 | 0.060 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2006 | 135 | 0.060 |
Why?
| | Isoquinolines | 1 | 2024 | 43 | 0.060 |
Why?
| | Skin Neoplasms | 1 | 2012 | 851 | 0.060 |
Why?
| | Risk Factors | 1 | 2019 | 10490 | 0.050 |
Why?
| | Neoplasm Proteins | 1 | 2007 | 435 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 755 | 0.050 |
Why?
| | Demography | 2 | 2015 | 296 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2023 | 83 | 0.050 |
Why?
| | Benzimidazoles | 1 | 2024 | 191 | 0.050 |
Why?
| | Recurrence | 2 | 2018 | 1108 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1449 | 0.050 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2021 | 38 | 0.040 |
Why?
| | Androgen Antagonists | 1 | 2022 | 92 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1724 | 0.040 |
Why?
| | Quality of Life | 1 | 2013 | 3024 | 0.040 |
Why?
| | Pulmonary Ventilation | 1 | 2021 | 83 | 0.040 |
Why?
| | Receptors, Androgen | 1 | 2022 | 153 | 0.040 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 142 | 0.040 |
Why?
| | Receptor, trkA | 1 | 2019 | 15 | 0.040 |
Why?
| | Receptor, trkC | 1 | 2019 | 10 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2019 | 74 | 0.040 |
Why?
| | Receptor, trkB | 1 | 2019 | 35 | 0.040 |
Why?
| | Trastuzumab | 1 | 2019 | 98 | 0.040 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 173 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 38 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2019 | 310 | 0.030 |
Why?
| | Phthalazines | 1 | 2018 | 63 | 0.030 |
Why?
| | Organic Cation Transporter 2 | 1 | 2017 | 8 | 0.030 |
Why?
| | Glutathione S-Transferase pi | 1 | 2017 | 10 | 0.030 |
Why?
| | Retroperitoneal Space | 1 | 2017 | 17 | 0.030 |
Why?
| | Organic Cation Transport Proteins | 1 | 2017 | 25 | 0.030 |
Why?
| | Urinary Diversion | 1 | 2017 | 13 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 48 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 490 | 0.030 |
Why?
| | Social Work | 1 | 2018 | 85 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 48 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 959 | 0.030 |
Why?
| | Laryngectomy | 1 | 2016 | 16 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 2018 | 255 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2018 | 325 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 159 | 0.030 |
Why?
| | Oncologists | 1 | 2017 | 43 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2017 | 108 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2018 | 218 | 0.030 |
Why?
| | Pelvis | 1 | 2017 | 117 | 0.030 |
Why?
| | Viral Core Proteins | 1 | 2016 | 22 | 0.030 |
Why?
| | Heart | 1 | 2020 | 616 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4414 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 1013 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 217 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 156 | 0.030 |
Why?
| | Random Allocation | 1 | 2016 | 369 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2006 | 1866 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1456 | 0.030 |
Why?
| | Antibodies, Neoplasm | 1 | 2015 | 33 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 911 | 0.030 |
Why?
| | Robotic Surgical Procedures | 1 | 2017 | 151 | 0.030 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2014 | 15 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1312 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 298 | 0.030 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 15 | 0.030 |
Why?
| | Receptor Cross-Talk | 1 | 2013 | 21 | 0.030 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 65 | 0.020 |
Why?
| | Metabolic Clearance Rate | 1 | 2012 | 115 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1655 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2014 | 552 | 0.020 |
Why?
| | Gene Silencing | 1 | 2013 | 198 | 0.020 |
Why?
| | Nausea | 1 | 2012 | 111 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 1007 | 0.020 |
Why?
| | Needs Assessment | 1 | 2014 | 388 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2098 | 0.020 |
Why?
| | Vomiting | 1 | 2012 | 128 | 0.020 |
Why?
| | Area Under Curve | 1 | 2012 | 324 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 700 | 0.020 |
Why?
| | Diarrhea | 1 | 2012 | 183 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1220 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2012 | 771 | 0.020 |
Why?
| | Fatigue | 1 | 2012 | 342 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2502 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 6951 | 0.020 |
Why?
| | Lung | 1 | 2021 | 4051 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 3295 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4599 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5222 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2079 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5948 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 5653 | 0.010 |
Why?
|
|
Bowles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|